Literature DB >> 18438604

Role of Nef in primate lentiviral immunopathogenesis.

F Kirchhoff1, M Schindler, A Specht, N Arhel, J Münch.   

Abstract

More than a decade ago it was established that intact nef genes are critical for efficient viral persistence and greatly accelerate disease progression in SIVmac-infected rhesus macaques and in HIV-1-infected humans. Subsequent studies established a striking number of Nef functions that evidently contribute to the maintenance of high viral loads associated with the development of immunodeficiency in the 'evolutionary-recent' human and the experimental macaque hosts. Recent data show that many Nef activities are conserved across different lineages of HIV and SIV. However, some differences also exist. For example, Nef alleles from most SIVs that do not cause disease in their natural monkey hosts, but not those of HIV-1 and its simian precursors, down-modulate TCR-CD3 to suppress T cell activation and programmed death. This evolutionary loss of a specific Nef function may contribute to the high virulence of HIV-1 in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438604     DOI: 10.1007/s00018-008-8094-2

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  60 in total

1.  Counteraction of HLA-C-mediated immune control of HIV-1 by Nef.

Authors:  Anke Specht; Amalio Telenti; Raquel Martinez; Jacques Fellay; Elizabeth Bailes; David T Evans; Mary Carrington; Beatrice H Hahn; David B Goldstein; Frank Kirchhoff
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

2.  The human immunodeficiency virus type 1 Nef and Vpu proteins downregulate the natural killer cell-activating ligand PVR.

Authors:  Giulia Matusali; Marina Potestà; Angela Santoni; Cristina Cerboni; Margherita Doria
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 3.  Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution?

Authors:  Frank Kirchhoff
Journal:  Nat Rev Microbiol       Date:  2009-03-23       Impact factor: 60.633

4.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

5.  Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins.

Authors:  Anke Heigele; Michael Schindler; Clement W Gnanadurai; Jolie A Leonard; Kathleen L Collins; Frank Kirchhoff
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

6.  HIV-1 Nef impairs heterotrimeric G-protein signaling by targeting Gα(i2) for degradation through ubiquitination.

Authors:  Prabha Chandrasekaran; Monica Buckley; Victoria Moore; Long Qin Wang; John H Kehrl; Sundararajan Venkatesan
Journal:  J Biol Chem       Date:  2012-10-15       Impact factor: 5.157

7.  A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells.

Authors:  Carina Banning; Jörg Votteler; Dirk Hoffmann; Herwig Koppensteiner; Martin Warmer; Rudolph Reimer; Frank Kirchhoff; Ulrich Schubert; Joachim Hauber; Michael Schindler
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

8.  Self-association of the Lentivirus protein, Nef.

Authors:  Youn Tae Kwak; Alexa Raney; Lillian S Kuo; Sarah J Denial; Brenda R S Temple; J Victor Garcia; John L Foster
Journal:  Retrovirology       Date:  2010-09-23       Impact factor: 4.602

9.  Conservation of Nef function across highly diverse lineages of SIVsmm.

Authors:  Jan Schmökel; Hui Li; Elizabeth Bailes; Michael Schindler; Guido Silvestri; Beatrice H Hahn; Cristian Apetrei; Frank Kirchhoff
Journal:  Retrovirology       Date:  2009-04-09       Impact factor: 4.602

10.  CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.

Authors:  Gudrun Strauss; Jonathan A Lindquist; Nathalie Arhel; Edward Felder; Sabine Karl; Tobias L Haas; Simone Fulda; Henning Walczak; Frank Kirchhoff; Klaus-Michael Debatin
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.